Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flunisolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.79 |
| ▸ | PGR | P06401 | 6/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | AR | P10275 | 2/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.79 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | IL5 | P05113 | 1/20 | 0.79 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.79 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.79 |
| ▸ | MMP9 | P14780 | 1/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.79 |
| ▸ | THPO | P40225 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flunisolide SCHEMBL17964229 | 0.90 | NR3C1 (0.83) | NR3C1CYP3A4PGRHIF1AABCB11 | |
| SCHEMBL8499750 | 0.89 | NR3C1 (0.74) | NR3C1CYP3A4PGRHIF1AABCB11 | |
| Budesonide SCHEMBL16731476 | 0.89 | NR3C1 (1.00) | NR3C1CYP3A4PGRHIF1AABCB11 | |
| Budesonide SCHEMBL1786635 | 0.89 | NR3C1 (1.00) | NR3C1CYP3A4PGRHIF1AABCB11 | |
| Budesonide SCHEMBL8056801 | 0.89 | NR3C1 (1.00) | NR3C1CYP3A4PGRHIF1AABCB11 | |
| Budesonide SCHEMBL13695912 | 0.89 | NR3C1 (1.00) | NR3C1CYP3A4PGRHIF1AABCB11 | |
| Budesonide SCHEMBL1130417 | 0.89 | NR3C1 (1.00) | NR3C1CYP3A4PGRHIF1AABCB11 | |
| Budesonide SCHEMBL13871728 | 0.89 | NR3C1 (1.00) | NR3C1CYP3A4PGRHIF1AABCB11 | |
| Budesonide SCHEMBL21570019 | 0.89 | NR3C1 (1.00) | NR3C1CYP3A4PGRHIF1AABCB11 | |
| Budesonide SCHEMBL14452945 | 0.89 | NR3C1 (1.00) | NR3C1CYP3A4PGRHIF1AABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114425049-A | Method for preparing carrier for pharmaceutical composition in form of inhalable dry powder | 正大天晴药业集团股份有限公司 | 2022-05-03 | — | — | CN | claimed |
| US-20090274771-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION (US) | 2009-11-05 | — | — | US | claimed |
| EP-3829641-B1 | NOVEL CARRIER PARTICLES FOR DRY POWDER FORMULATIONS FOR INHALATION | CHIESI FARM SPA (IT) | 2024-05-22 | — | — | EP | disclosed |
| CN-112469443-B | Novel carrier particles for dry powder formulations for inhalation | 奇斯药制品公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11813360-B2 | Carrier particles for dry powder formulations for inhalation | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-11-14 | — | — | US | disclosed |
| EP-3405173-B1 | PREPARATION OF MICRONIZED PARTICLES OF AN ANTIMUSCARINIC COMPOUND BY HYDRODYNAMIC CAVITATION | CHIESI FARM SPA (IT) | 2022-12-07 | — | — | EP | disclosed |
| CN-114425049-A | Method for preparing carrier for pharmaceutical composition in form of inhalable dry powder | 正大天晴药业集团股份有限公司 | 2022-05-03 | — | — | CN | disclosed |
| US-20210290540-A1 | NOVEL CARRIER PARTICLES FOR DRY POWDER FORMULATIONS FOR INHALATION | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-09-23 | — | — | US | disclosed |
| EP-3829641-A1 | NOVEL CARRIER PARTICLES FOR DRY POWDER FORMULATIONS FOR INHALATION | Chiesi Farmaceutici S.p.A. (IT) | 2021-06-09 | — | — | EP | disclosed |
| WO-2021058454-A1 | NOVEL CARRIER PARTICLES FOR DRY POWDER FORMULATIONS FOR INHALATION | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-04-01 | — | — | WO | disclosed |
| CN-112469443-A | Novel carrier particles for dry powder formulations for inhalation | 奇斯药制品公司 | 2021-03-09 | — | — | CN | disclosed |
| US-6893628-B2 | Mixture of tetrafluoroethane propellant and drug | GLAXO GROUP LIMITED (GB) | 2005-05-17 | — | — | US | disclosed |
| US-20030165437-A1 | Mixture of tetrafluoroethane propellant and drug | GLAXO GROUP LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| US-20020031479-A1 | Aerosol formulation of particulate drug, fluorocarbon or hydrogen-containing chlorofluorocarbon propellant; surfactant-free, and the drug is not salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate | GLAXO GROUP LIMITED | 2002-03-14 | — | — | US | disclosed |
| US-6306369-B1 | COMPRISING BRONCHODILATORY AGENT, ANTI-INFALMMATORY AGENT AND 1,1,1,2-TETRAFLUOROETHANE PROPELLENT; FOR ADMINISTRATION OF MEDICAMENTS BY INHALATION; FOR THERAPY OF RESPIRATORY SYSTEM DISORDERS | GLAXO GROUP LIMITED (GB) | 2001-10-23 | — | — | US | disclosed |
| US-6200549-B1 | CONTAINS LESS THAN 0.0001% W/W SURFACTANT BASED UPON THE WEIGHT OF MEDICAMENT | GLAXO GROUP LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| US-5922306-A | INHALANTS DISPERSION COMPRISING TETRAFLUOROETHANE/1,1,1,2-/ PROPELLANT, DRUG PARTICLES PRECOATED WITH SURFACTANT, THE DRUG FORMULATION CONSISTS OF BETAMETHASONE, ERGOTAMINE TARTRATE OR SODIUM CROMOGLYCATE FOR RESPIRATORY SYSTEM DISORDERS | GLAXO GROUP LIMITED (GB) | 1999-07-13 | — | — | US | disclosed |
| US-5744123-A | Aerosol formulations containing P134a and particulate medicaments | GLAXO GROUP LIMITED (GB) | 1998-04-28 | — | — | US | disclosed |
| EP-0783302-A1 | MEDICAMENTS | GLAXO WELLCOME INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996009816-A1 | MEDICAMENTS | GLAXO WELLCOME INC. (US) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274771-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | TSLP, CHRM3, RGS17 | NR3C1 300/4885CYP3A4 4477/4885PGR 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.